I undersøgelsen med HBeAg- positive patienter resulterede behandling i mere end 48 uger i yderligere reduktioner af serum- HBV- DNA- niveauerne samt i en øget andel af patienter med ALAT - normalisering, HBeAg- tab og serokonversion.
In the HBeAg positive study, treatment beyond 48 weeks resulted in further reductions in serum HBV DNA levels and increases in the proportion of patients with ALT normalisation, HBeAg loss and seroconversion.